Viral kinetic study of VX 135 monotherapy in patients with genotype 1 hepatitis C and cirrhosis, and in patients with genotypes 2, 3 or 4 HCV infection

Trial Profile

Viral kinetic study of VX 135 monotherapy in patients with genotype 1 hepatitis C and cirrhosis, and in patients with genotypes 2, 3 or 4 HCV infection

Completed
Phase of Trial: Phase II

Latest Information Update: 01 May 2013

At a glance

  • Drugs VX 135 (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 May 2013 New trial record
    • 30 Apr 2013 Results were presented at the 48th Annual Meeting of the European Association for the Study of the Liver (EASL), according to a Vertex Pharmaceuticals media release.
    • 23 Apr 2013 Results from this trial will be presented at the 48th Annual Meeting of the European Association for the Study of the Liver (EASL), according to a Vertex Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top